Follow the Vitrolife AB stock price and the full insider trade history of the company, a listed equity based in Finland. Shares trade on the FI market, under the oversight of FIN-FSA. Operating in the Health Care sector, Vitrolife AB has recorded 3 public disclosures. Market capitalisation: €11.9bn. The latest transaction was reported on 6 February 2026 (Purchase). Among the most active insiders: Bronwyn Brophy O'Connor. The full history is openly available.
Analysts rate Vitrolife AB Strong Buy (bullish), based on 5 analysts. Average price target: SEK 129.60.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
Vitrolife AB is a company in the healthcare and pharmaceutical sector, providing solutions for fertility and embryonic development. It is listed on the XSTO stock exchange.